CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection

Bibliography

• Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Barrett LJ, Prakash C, Urea protects Helicobacter (campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 1990;99:697-702
   PubMed Web of Science ®Google Scholar
• Marshall BJ, McGechie DB, Rogers PA, Pyloric campylobacter infection and gastroduodenal disease. Med J Aust 1985;142:439-44
   PubMed Web of Science ®Google Scholar
• Moss SF, Sood S. Helicobacter pylori. Curr Opin Infect Dis 2003;16:445-51
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, Morain CO, Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81
   PubMed Web of Science ®Google Scholar
• Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007;8:2701-17
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-51
   PubMed Web of Science ®Google Scholar
• Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 2005;59:709-15
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2-8
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5:181-202
   PubMed Web of Science ®Google Scholar
• Shin JM, Besancon M, Bamberg K, Structural aspects of the gastric H+, K+ ATPase. Ann NY Acad Sci 1997;834:65-76
   Google Scholar
• Sachs G, Shin JM, Briving C, The pharmacology of the gastric acid pump. The H+, K+ ATPase. Ann Rev Pharmacol Toxicol 1995;35:277-305
   PubMed Web of Science ®Google Scholar
• Besancon M, Simon A, Sachs G, Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438-46
   PubMed Web of Science ®Google Scholar
• Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998;56:307-35
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Shibata H, Oketani K, Inhibitons of acid secretion by E3810 and omeprazole and their reversal by glutathione. Biochem Pharmacol 1991;42:321-8
   PubMed Web of Science ®Google Scholar
• Yasuda S, Horai Y, Tomono Y, Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995;58:143-54
   PubMed Web of Science ®Google Scholar
• Andersson T, Holmberg J, Röhss K, Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole and pantoprazole. Br J Clin Pharmacol 1998;45:369-75
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson T, Ahlström M, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7
   PubMed Web of Science ®Google Scholar
• Fock KM, Ang TL, Bee LC, Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008;47:1-6
   PubMed Web of Science ®Google Scholar
• Shin JM, Choo YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+/K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004;126:7800-11
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:411-26
   PubMed Web of Science ®Google Scholar
• Product Information: KAPIDEX(R) delayed release capsules, dexlansoprazole delayed release capsules. Takeda Pharmaceuticals America, Inc, Deerfield, IL; 2009
   Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl. 3):27-36
   PubMed Web of Science ®Google Scholar
• Äbelö A, Andersson T, Antonsson M, Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Disp 2000;28:966-72
   PubMed Web of Science ®Google Scholar
• Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004;94:106-11
   PubMed Web of Science ®Google Scholar
• Liu KH, Kim MJ, Jung WM, Lansoprazole enantiomers activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos 2005;33:209-13
   PubMed Web of Science ®Google Scholar
• Vakily M, Lee RD, Wu J, Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation. Clin Drug Invest 2009;29:35-50
   PubMed Web of Science ®Google Scholar
• Bastaki SM, Chandranath I, Garner A. Comparison of five antisecretory agents acting via gastric H+/K+-ATPase. J Physiol Paris 2000;94:19-23
   PubMed Web of Science ®Google Scholar
• Pantoflickova D, Dorta G, Ravic M, Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003;17:1507-14
   PubMed Web of Science ®Google Scholar
• Miner P, Katz PO, Chen YS, Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20
   PubMed Web of Science ®Google Scholar
• Morii M, Hamatani K, Takeguchi N. The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+, K+-ATPase. Biochem Pharmacol 1995;49:1729-34
   PubMed Web of Science ®Google Scholar
• Huber R, Kohl B, Sachs G, Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995;9:363-78
   PubMed Web of Science ®Google Scholar
• Barth J, Hahne W. Review article: rabeprazole-based therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16(Suppl 1):31-3
   PubMed Web of Science ®Google Scholar
• Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999;58:725-42
   PubMed Web of Science ®Google Scholar
• Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78
   PubMed Web of Science ®Google Scholar
• Martin de Argila C. Safety of potent gastric acid inhibition. Drugs 2005;65(Suppl 1): 97-104
   PubMed Web of Science ®Google Scholar
• Aseeri M, Schroeder T, Kramer J, Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-13
   PubMed Web of Science ®Google Scholar
• Lowe DO, Mamdani MM, Kopp A, Proton pump inhibitors and hospitalization for clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006;43:1272-6
   PubMed Web of Science ®Google Scholar
• Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 1998;329(Pr 1):17-35
   PubMed Web of Science ®Google Scholar
• Wedlund PJ, Aslanian WS, McAllister CB, Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC, Becker GW, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4’-hydroxylation. Arch Biochem Biophys 1993;306:240-5
   PubMed Web of Science ®Google Scholar
• Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9
   PubMed Web of Science ®Google Scholar
• Nakamura K. Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8
   PubMed Web of Science ®Google Scholar
• Horai Y, Nakano M, Ishizaki T, Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207
   PubMed Web of Science ®Google Scholar
• Sohn DR, Kusaka M, Ishizaki T, Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Lou YQ, Du YL, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephynytoin. Clin Pharmacol Ther 1992;51:388-97
   PubMed Web of Science ®Google Scholar
• Ward SA, goto F, Nakamura K, S-Mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther 1987;42:96-9
   PubMed Web of Science ®Google Scholar
• Inaba T, Jurima M, Kalow W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 1986;38:768-42
   PubMed Web of Science ®Google Scholar
• Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000;64:174-83
   Web of Science ®Google Scholar
• Blaisdell J, Mohrenweiser H, Jackson J, Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 2002;12:703-11
   PubMedGoogle Scholar
• Morita J, Kobayashi K, Wanibuchi A, A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4′-hydroxylation. Drug Metab Pharmacokinet 2004;19:236-8
   PubMedGoogle Scholar
• Sim SC, Risinger C, Dahl ML, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-13
   PubMed Web of Science ®Google Scholar
• Hanioka N, Tsuneto Y, Saito Y, Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica 2007;37:342-55
   PubMed Web of Science ®Google Scholar
• Chang M, Dahl ML, Tybring g, Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63
   PubMedGoogle Scholar
• Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-6
   PubMed Web of Science ®Google Scholar
• de Morais SMF, Wilkinson GR, Blaisdell J, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22
   PubMed Web of Science ®Google Scholar
• de Morais SMF, Wilkinson GR, Blaisdell J, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Ishizaki T, Chiba K, Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64
   PubMedGoogle Scholar
• de Morais SM, Goldstein JA, Xie HG, Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11
   PubMed Web of Science ®Google Scholar
• Roh HK, Dahl ML, Johansson I, Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996;6:441-7
   PubMedGoogle Scholar
• Brøsen K, de Morais SMF, Meyer UA, A multifamily study on the relationship between CYP2C19 genotype and S-mepheytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7
   PubMedGoogle Scholar
• Ishizaki T, Sohn DR, Kobayashi K, Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994;16:214-5
   PubMed Web of Science ®Google Scholar
• Horai Y, Kimura M, Furuie H, Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001;15:793-803
   PubMed Web of Science ®Google Scholar
• Sohn DR, Kwon JT, Kim HK, Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4’-hydroxylation phenotype status. Clin Pharmacol Ther 1997;61:574-82
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ohkubo T, Otani K, Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997;62:619-28
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38:243-70
   PubMed Web of Science ®Google Scholar
• Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2-8
   PubMed Web of Science ®Google Scholar
• Shirai N, Furuta T, MoriyamaY, Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001;15:1929-37
   PubMed Web of Science ®Google Scholar
• Ieiri I, Kishimoto Y, Okochi H, Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 2001;57:485-92
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Takashima M, Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341-8
   PubMedGoogle Scholar
• Fujioka T, Kawasaki H, Su W, In vitro anti microbial activity against H. pylori and clinical efficacy of various drugs. Jpn J Clin Med 1993;51:3255-60
   PubMedGoogle Scholar
• Lin CJ, Yang JC, Uang YS, Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003;23:711-19
   PubMed Web of Science ®Google Scholar
• Yang JC, Yang YF, Uang YS, Pharmacokinetic-pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol 2009;67:503-10
   PubMed Web of Science ®Google Scholar
• Williams MP, Blanshard C, Millson C, A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 2000;14:691-9
   PubMed Web of Science ®Google Scholar
• Lew EA, Barbuti RC, Kovacs TOG, An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 1998;12:667-72
   PubMed Web of Science ®Google Scholar
• Furuta T, Ohashi K, Kamata T, Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-30
   PubMed Web of Science ®Google Scholar
• Padol S, Yuan Y, Thabane M, The effect of CYP2C19 polymorphisms on eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006;101:1467-75
   PubMed Web of Science ®Google Scholar
• Yang JC, Chern HD, Chen WH, Relation of metabolic rate of omeprazole and eradication of Helicobacter pylori infection: a pharmacogenetic study [abstract]. Gut 1998;43:A79
   PubMed Web of Science ®Google Scholar
• Sagar M, Tybring G, Dahl ML, Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000;119:670-6
   PubMed Web of Science ®Google Scholar
• Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43
   PubMed Web of Science ®Google Scholar
• Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL. editors, Helicobacter pylori: Physiology and genetics. ASM Press: Washington DC; 2001. p. 511-30
   Google Scholar
• Sugimoto M, Furuta T, Shirai N, Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacer 2007;12:317-23
   PubMed Web of Science ®Google Scholar
• Labenz J, Stolte M, Blum AL, Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995;37:39-43
   Google Scholar
• Mégraud F. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro. J Clin Gastroenterol 1995;20(Suppl 1):S24-7
   PubMed Web of Science ®Google Scholar
• Grayson ML, Eliopoulos GM, Ferraro MJ, Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989;8:888-9
   PubMed Web of Science ®Google Scholar
• Lai YC, Yang JC, Huang SH. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol 2004;10:991-4
   PubMed Web of Science ®Google Scholar
• Masconi G, Parente F, Russo A, Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-66
   PubMed Web of Science ®Google Scholar
• Iwahi T, Satoh H, Nakao M, Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6
   PubMed Web of Science ®Google Scholar
• Weil J, Bell GD, Powell K, Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991;5:309-13
   PubMed Web of Science ®Google Scholar
• Nagata K, Satoh H, Iwahi T, Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: Unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993;37:769-74
   PubMed Web of Science ®Google Scholar
• Fujiyama K, Fujioka T, Kodama R, Effect of E3810, a novel proton pump inhibitor, against Helicobacter pylori [abstract]. Am J Gastroenterol 1994;89:1371
   Google Scholar
• Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996;19:182-7
   PubMed Web of Science ®Google Scholar
• Tsuchiya M, Imamura L, Park JB, Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995;18:1053-6
   PubMed Web of Science ®Google Scholar
• Lee A, Fox J, Hazell S. Pathogenicity of Helicobacter pylori: a perspective. Infect Immun 1993;61:1601-10
   PubMed Web of Science ®Google Scholar
• Tsutsui N, Taneike I, Ohara T, A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the mobility of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:3069-73
   PubMed Web of Science ®Google Scholar
• Zullo A, Vaira D, Vakil N, High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26
   PubMed Web of Science ®Google Scholar
• De Francesco V, A. Zullo A, Hassan C, et al. The prolongation of triple therapy for does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig Liver Dis 2004;36:322-6
   PubMedGoogle Scholar
• Vaira D, Zullo A, Vakil, Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial Ann Intern Med 2007;146:556-63
   Google Scholar
• Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96
   PubMed Web of Science ®Google Scholar
• Bayerdörffer E, Miehlke S, Mannes GA, Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-7
   PubMed Web of Science ®Google Scholar
• Miehlke S, Kirsch C, Schneider-Brachert W, A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8:310-9
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Takashima M, Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158-68
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Xiao F, High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003;50:2274-8
   PubMed Web of Science ®Google Scholar
• Shirai N, Sugimoto M, Kodaira C, Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as the rescue regimen for Helicobacter pylori infection after triple therapy. Eur J Clin Pharmacol 2007;63:743-49
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Kodaira M, Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-28
   PubMed Web of Science ®Google Scholar
• Athamna A, Athamna M, Medlej B, In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on bacillus anthracis. J Antimicrob Chemother 2004;53:609-15
   PubMed Web of Science ®Google Scholar
• Vakil N, Lanza F, Schwartz H, Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
   PubMed Web of Science ®Google Scholar
• Heep M, Kist M, Strobel S, Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41
   PubMed Web of Science ®Google Scholar
• Peitz U, Sulliga M, Wolle K, High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Mégraud F, Lopez-Brea M, European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-23
   PubMed Web of Science ®Google Scholar
• Meyer JM, Silliman NP, Wang W, Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136:13-24
   PubMed Web of Science ®Google Scholar
• Midolo PD, Turnidge JD, Munckhof WJ. Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent? Antimicrob Agents Chemother 1996;40:1327-28
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998;35:391-402
   PubMed Web of Science ®Google Scholar